Ketorolac intranasal - Egalet

Drug Profile

Ketorolac intranasal - Egalet

Alternative Names: Ketorolac trometamol intranasal; Ketorolac trometamol nasal spray; Ketorolac tromethamine intranasal; Ketorolac tromethamine nasal spray; ROX-828; ROX-888; Sprix

Latest Information Update: 08 Mar 2016

Price : $50

At a glance

  • Originator ROXRO PHARMA
  • Developer Egalet; Luitpold Pharmaceuticals; ROXRO PHARMA
  • Class 2 ring heterocyclic compounds; Carboxylic acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrroles; Small molecules
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Acute pain
  • Phase III Postoperative pain
  • Discontinued Migraine

Most Recent Events

  • 08 Mar 2016 Phase-III development for Pain (In adolescents, In children, In infants, In neonates) is ongoing in USA (Intranasal)
  • 08 Feb 2016 Ketorolac nasal is licensed to Septodont in USA for Pain
  • 14 Dec 2015 Ketorolac intranasal spray is available for licensing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top